KPV
NeuroprotectionNeurology research on KPV examines whether this α-msh-derived anti-inflammatory tripeptide produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: suppresses nf-κb activation and il-1β release stabilises mast cells. antimicrobial against c. albicans and s. aureus. acts on gut mucosa to reduce inflammation in ibd models. does not engage melanocortin receptors strongly, avoiding tanning effects.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. KPV is dosed at 200-500 mcg 1-2x daily subq or oral via subq/oral/topical in cognitive-focused protocols, with the Short (minutes) pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: KPV acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Suppresses NF-κB activation and IL-1β release. Neuro dose: 200-500 mcg 1-2x daily subq or oral via subq/oral/topical; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Three pathways shape KPV's cognitive profile: Suppresses NF-κB activation and IL-1β release. Stabilises mast cells. Antimicrobial against C. albicans and S. aureus. Acts on gut mucosa to reduce inflammation in IBD models. Does not engage melanocortin receptors strongly, avoiding tanning effects. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.
Central nervous system access
KPV reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq/oral/topical route(s) and Short (minutes) half-life set the timeline for CNS exposure. Suppresses NF-κB activation and IL-1β release. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Monoamine and neurotrophic effects
KPV's downstream effects on monoamine systems (dopamine, serotonin, occasionally noradrenaline) and on neurotrophic signalling (BDNF, NGF, NT-3) form the molecular substrate of its observed cognitive phenotype. Suppresses NF-κB activation and IL-1β release. Stabilises mast cells. Antimicrobial against C. albicans and S. aureus. Acts on gut mucosa to reduce inflammation in IBD models. Does not engage melanocortin receptors strongly, avoiding tanning effects. For users tracking cognitive endpoints over the typical 1-2x daily subq or oral dosing pattern at 200-500 mcg, the changes accumulate across 4–8 weeks rather than emerging acutely. The relevant clinical endpoints are sleep quality, recovery capacity, mood stability, and resilience to cognitive stressors.
Receptor pharmacology and selectivity profile
KPV's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Suppresses NF-κB activation and IL-1β release. Stabilises mast cells. Antimicrobial against C. albicans and S. aureus. Acts on gut mucosa to reduce inflammation in IBD models. Does not engage melanocortin receptors strongly, avoiding tanning effects. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing KPV with peptides engaging the same primary receptor produces competition rather than synergy.
Neuroprotection is one of the more-reported subjective benefits of KPV across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For bdnf support, KPV is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where KPV is used for hpa axis modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Neurogenesis is one of the more-reported subjective benefits of KPV across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-500 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 200-500 mcg | 1-2x daily SubQ or oral |
| Maintenance phase | SubQ | 140-500 mcg | Ongoing with periodic pauses |
Dose timing for KPV is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
KPV stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- KPV + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with KPV's mechanism in cognitive / neurological protocols.
- KPV + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with KPV's mechanism in cognitive / neurological protocols.
- KPV + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with KPV's mechanism in cognitive / neurological protocols.
- KPV + DSIP: Mechanism remains incompletely characterised. Pairs naturally with KPV's mechanism in cognitive / neurological protocols.
Excellent tolerability. No pigmentation effects.
Lens-specific safety considerations for cognitive / neurological use of KPV: Excellent tolerability. No pigmentation effects. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| KPV | α-MSH-derived anti-inflammatory tripeptide | Short (minutes) | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
How long until I notice cognitive effects?
Cognitive side effects to watch for?
Best route for cognitive applications — injection or oral?
Can KPV be stacked with other nootropics?
What is the regulatory status of KPV?
How does KPV compare to Semax and Selank?
Start a KPV Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified KPV and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 342 Da
- Sequence length
- 3 aa
- Half-life
- Short (minutes)
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small clinical series
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for KPV unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for KPV
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised